Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:FDA
gptkb:EMA December 2020 multiple countries |
| gptkbp:average_temperature |
-80 to -60 degrees Celsius
|
| gptkbp:clinical_trial |
multiple countries
Phase 3 over 43,000 prevention of COVID-19 |
| gptkbp:communication |
gptkb:Educational_Institution
public health campaigns |
| gptkbp:developed_by |
gptkb:Pfizer
Bio N Tech |
| gptkbp:distribution |
global
|
| gptkbp:dosage_form |
gptkb:battle
2 |
| gptkbp:effective_date |
December 11, 2020
|
| https://www.w3.org/2000/01/rdf-schema#label |
Comirnaty
|
| gptkbp:is_effective_against |
95%
|
| gptkbp:is_vulnerable_to |
government agencies
international organizations research institutions ongoing studies WHO guidelines lipid nanoparticle effectiveness studies against variants safety data collection reduction in COVID-19 cases viral vector vaccine against severe disease against hospitalization against symptomatic infection reduction in deaths reduction in hospitalizations CDC guidelines standard refrigerator through healthcare providers two doses 21 days apart |
| gptkbp:launch_date |
September 2021
|
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
Pfizer-Bio N Tech
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
gptkb:Comirnaty
|
| gptkbp:regulatory_compliance |
conditional
|
| gptkbp:safety_features |
VAERS
EHR data |
| gptkbp:shelf_life |
6 months
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever joint pain chills injection site pain |
| gptkbp:supply_chain |
cold chain logistics
|
| gptkbp:target_audience |
gptkb:Person
adults adolescents |
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
gptkb:vaccine
gptkb:drug |
| gptkbp:updates |
new formulations
|
| gptkbp:bfsParent |
gptkb:Pfizer
|
| gptkbp:bfsLayer |
3
|